These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32615260)

  • 1. Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability.
    Markovic M; Zur M; Dahan A; Cvijić S
    Eur J Pharm Sci; 2020 Sep; 152():105440. PubMed ID: 32615260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier.
    Huang BB; Li GF; Luo JH; Duan L; Nobuaki K; Akira Y
    World J Gastroenterol; 2008 Aug; 14(31):4928-37. PubMed ID: 18756602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide.
    Markovic M; Zur M; Ragatsky I; Cvijić S; Dahan A
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33276565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Permeabilities of rebamipide via different intestinal mucosa in the diffusion chamber in vitro].
    Li GF; Wang CX; Yan Y; Kishimoto N; Yamamoto A
    Yao Xue Xue Bao; 2008 Mar; 43(3):314-7. PubMed ID: 18630271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mimicking regional and fasted/fed state conditions in the intestine with the mucus-PVPA in vitro model: The impact of pH and simulated intestinal fluids on drug permeability.
    Falavigna M; Klitgaard M; Steene E; Flaten GE
    Eur J Pharm Sci; 2019 Apr; 132():44-54. PubMed ID: 30822502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of lipid solubility and oral bioavailability of a poorly water- and poorly lipid-soluble drug, rebamipide, by utilizing its counter ion and SNEDDS preparation.
    Okawa S; Sumimoto Y; Masuda K; Ogawara KI; Maruyama M; Higaki K
    Eur J Pharm Sci; 2021 Apr; 159():105721. PubMed ID: 33482317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats.
    Shin BS; Kim CH; Jun YS; Yoon CH; Rho JI; Lee KC; Han HS; Yoo SD
    Drug Dev Ind Pharm; 2004 Sep; 30(8):869-76. PubMed ID: 15521332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
    Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B
    Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy.
    Tung NT; Park CW; Oh TO; Kim JY; Ha JM; Rhee YS; Park ES
    J Pharm Pharmacol; 2011 Dec; 63(12):1539-47. PubMed ID: 22060284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation.
    Dahan A; González-Álvarez I
    Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33671434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebamipide suppresses diclofenac-induced intestinal permeability via mitochondrial protection in mice.
    Diao L; Mei Q; Xu JM; Liu XC; Hu J; Jin J; Yao Q; Chen ML
    World J Gastroenterol; 2012 Mar; 18(10):1059-66. PubMed ID: 22416180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa.
    Suetsugu H; Ishihara S; Moriyama N; Kazumori H; Adachi K; Fukuda R; Watanabe M; Kinoshita Y
    J Lab Clin Med; 2000 Jul; 136(1):50-7. PubMed ID: 10882227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding
    B Shekhawat P; B Pokharkar V
    Acta Pharm Sin B; 2017 May; 7(3):260-280. PubMed ID: 28540164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biopharmaceutics of successful controlled release drug product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract.
    Zur M; Cohen N; Agbaria R; Dahan A
    Int J Pharm; 2015 Jul; 489(1-2):304-10. PubMed ID: 25957705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of intra-rectal administration of rebamipide on dextran sulfate sodium-induced rat colitis.
    Okayama M; Tsubouchi R; Nishio H; Kato S; Takeuchi K
    Digestion; 2004; 70(4):240-9. PubMed ID: 15687726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering a Remedy to Modulate and Optimize Biopharmaceutical Properties of Rebamipide by Synthesizing New Cocrystal: In Silico and Experimental Studies.
    Jindal A; Singh R; Tomar S; Dureja J; Karan M; Chadha R
    Pharm Res; 2021 Dec; 38(12):2129-2145. PubMed ID: 34904202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.